<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04160390</url>
  </required_header>
  <id_info>
    <org_study_id>18358</org_study_id>
    <secondary_id>NCI-2019-07376</secondary_id>
    <secondary_id>18358</secondary_id>
    <secondary_id>U01CA239373</secondary_id>
    <nct_id>NCT04160390</nct_id>
  </id_info>
  <brief_title>Blood Samples to Identify Biomarkers in Patients Treated With Cyclophosphamide After Donor Stem Cell Transplant</brief_title>
  <official_title>Blood Samples to Identify Biomarkers for Post-Transplant Cyclophosphamide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial uses blood samples to understand how patients' bodies process and respond to a&#xD;
      drug called cyclophosphamide given after a donor stem cell transplant. Identifying biomarkers&#xD;
      (molecules that can indicate normal or abnormal processes) may help researchers develop a&#xD;
      blood test that can be used to predict how well patients will process and respond to&#xD;
      cyclophosphamide.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine whether endogenous metabolomics compounds obtained before cyclophosphamide&#xD;
      administration can predict the ratio of 4hydroxycyclophosphamide to cyclophosphamide area&#xD;
      under the curve (4HCY/CY AUC).&#xD;
&#xD;
      II. To validate mathematic models of CY and mycophenolic acid (MPA) pharmacokinetics and&#xD;
      develop mathematic models including these pharmacokinetics, -omics data and clinical&#xD;
      outcomes.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess if recipients' metabolomics and pharmacokinetics (e.g., CY and it's metabolites&#xD;
      AUCs) are associated with acute graft versus host disease (GVHD) and other clinical outcomes.&#xD;
&#xD;
      II. To assess the association of the intestinal microbiome with the plasma metabolome, acute&#xD;
      GVHD and other clinical outcomes.&#xD;
&#xD;
      III. To obtain donor blood samples at one time pre-transplant and assess if donors'&#xD;
      metabolomics are associated with acute GVHD and other clinical outcomes.&#xD;
&#xD;
      EXPLORATORY OBJECTIVE:&#xD;
&#xD;
      I. Donor and recipient germline deoxyribonucleic acid (DNA) isolation and genomic analysis.&#xD;
&#xD;
      OUTLINE: Participants are assigned to 1 of 2 arms.&#xD;
&#xD;
      ARM I (PATIENTS RECEIVING A HAPLOIDENTICAL TRANSPLANT): Patients undergo collection of blood&#xD;
      prior to transplant, on day 0, days 3-7, day 14, and day 21. Patients also undergo collection&#xD;
      of saliva prior to transplant and collection of stool prior to and post-transplant. Donors&#xD;
      undergo collection of blood and saliva within 8 weeks prior to donation.&#xD;
&#xD;
      ARM II (PATIENTS RECEIVING A NON-HAPLOIDENTICAL TRANSPLANT): Patients undergo collection of&#xD;
      blood prior to transplant and on days 0, 3, and 4. Patients also undergo collection of stool&#xD;
      prior to and post-transplant. Donors undergo collection of blood and saliva within 8 weeks&#xD;
      prior to donation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Temporarily closed to accrual by IRB&#xD;
  </why_stopped>
  <start_date type="Actual">November 13, 2018</start_date>
  <completion_date type="Anticipated">October 24, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 24, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mathematical models of cyclophosphoramide (CY) and mycophenolic acid pharmacokinetics (PK) with t cell effects.</measure>
    <time_frame>Up to day 21</time_frame>
    <description>Will determine whether readily available patient characteristics influence CY PK using population (pop)PK modeling. Will validate our existing popPK model of CY, 4HCY, and carboxyethylphosphoramide mustard.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute GVHD</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Cumulative incidence estimates will be calculated with appropriate accounting for competing risks. Adjusted hazard ratios will be estimated via Cox regression models.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Allogeneic Hematopoietic Stem Cell Transplant Recipient</condition>
  <condition>Donor</condition>
  <condition>Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>Arm I (biospecimen collection)</arm_group_label>
    <description>Patients undergo collection of blood prior to transplant, on day 0, days 3-7, day 14, and day 21. Patients also undergo collection of saliva prior to transplant and collection of stool prior to and post-transplant. Donors undergo collection of blood and saliva within 8 weeks prior to donation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (biospecimen collection)</arm_group_label>
    <description>Patients undergo collection of blood prior to transplant and on days 0, 3, and 4. Patients also undergo collection of stool prior to and post-transplant. Donors undergo collection of blood and saliva within 8 weeks prior to donation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biospecimen Collection-Blood</intervention_name>
    <description>Undergo collection of blood</description>
    <arm_group_label>Arm I (biospecimen collection)</arm_group_label>
    <arm_group_label>Arm II (biospecimen collection)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biospecimen Collection-Stool</intervention_name>
    <description>Undergo collection of stool</description>
    <arm_group_label>Arm I (biospecimen collection)</arm_group_label>
    <arm_group_label>Arm II (biospecimen collection)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, saliva, stool&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients of the City of Hope Comprehensive Cancer Center and donors.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Scheduled to undergo first allogeneic hematopoietic cell transplant (HCT)&#xD;
&#xD;
          -  Allogeneic HCT scheduled to treat any underlying disease. Patients with nonmalignant&#xD;
             diseases or cancer are eligible&#xD;
&#xD;
          -  Scheduled to receive post-transplant cyclophosphamide (any dose, any number of doses,&#xD;
             any dosing frequency) as part of their post-graft immunosuppression or GVHD&#xD;
             prophylaxis. Patients enrolled on treatment protocols that include post transplant&#xD;
             cyclophosphamide (PTCy) but do not include mycophenolate mofetil (MMF) or tacrolimus&#xD;
             can participate&#xD;
&#xD;
          -  Willingness to:&#xD;
&#xD;
               -  Provide blood&#xD;
&#xD;
               -  Permit medical record review&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeannine S McCune</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 8, 2019</study_first_submitted>
  <study_first_submitted_qc>November 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2019</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

